The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been Downgraded to Sector Perform from Outperform by RBC Capital Mkts in its latest research note that was published on May 24. BCRX was given a price target of $4.50 by RBC Capital Mkts, with other Wall Street analysts also giving their reports regarding the stock. Piper Jaffray, analysts launched coverage of BCRX stock with a Overweight rating, according to their flash note to investors on November 16.
BioCryst Pharmaceuticals, Inc., which has current market capitalization of above $348 Million, published its last quarter earnings on June 30, 2019.
BCRX surged by $0.01 during the normal trading session on Thursday and reaching a high of $3.30 during the day while it closed the day at $3.15. The BioCryst stock had a low trading volume of 1.05 million shares on that day, which is low compared to the average daily volume of 1.42M shares. BCRX has also gained 0.32% of its value over the past 7 days. However, the stock has declined by 9.48% in the 3 months of the year. Over the past six months meanwhile, it has lost 61.54% while it has lost 60.97% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -20.85% from its 3 months high price. However, taking another look at BCRX will indicate that it is trading +26.51% away from its 90-day low. Looking at the bigger picture, the BioCryst Pharmaceuticals, Inc. stock has dropped by -68.34% from its 52-week high while it has surged by +26.51% from its 52-week low price.
On May 22, 2019 ASELAGE STEVE, Director bought 3000 shares of the company. The average price for that transaction was $3.57 per share, which meant that ASELAGE STEVE spent $10710 purchasing the stocks. The purchase was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Senior Vice President and CFO, STAAB THOMAS R II selling 9750 shares of this stock on May 17, 2019. The average selling price for the stock was $7.65 per share, with the sold stock accruing $74587.5. Following this transaction, the Senior Vice President and CFO STAAB THOMAS R II now holds 134926 shares of the company, which is worth around $443906.5.
BioCryst has around 35 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $72 Billion. The BioCryst stock is bringing in revenue of over 12 months, which is roughly 1 Billion. Despite all that, BioCryst Pharmaceuticals, Inc. is seeing things declining very much as their y-o-y quarterly revenue dropped by -88.41%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 47.31%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 75.86%. Over the past 20 days, BioCryst’s Stochastic %K stood at 89.27% while its Stochastic %D was revealed to be 91.78%.